Legal / IP

Transcenta Granted Chinese Invention Patent for Anti‑CLDN18.2 Antibodies – Protecting the Companion Diagnostic for Osemitamab (TST001) in Gastric Cancer
HKG: 6628Patents

Transcenta Granted Chinese Invention Patent for Anti‑CLDN18.2 Antibodies – Protecting the Companion Diagnostic for Osemitamab (TST001) in Gastric Cancer

Transcenta Holding Limited (HKG: 6628) announced that it has been granted an invention patent by the China National Intellectual Property Administration (CNIPA) covering the anti-CLDN18.2 antibodies independently developed by the…

Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA

WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation

WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Chipscreen's Epidaza Patent Faces Invalidation Request Review
CancerChia Tai Tianqing Pharmaceutical

Chipscreen’s Epidaza Patent Faces Invalidation Request Review

Novartis to Defend Entresto Patent After CAFC Ruling
CVDNovartis

Novartis to Defend Entresto Patent After CAFC Ruling

SynCardia's Next-Generation Artificial Heart Granted Patent in China
CVDPatents

SynCardia’s Next-Generation Artificial Heart Granted Patent in China

Roche’s Evrysdi Receives Patent Term Extension in China, Extending Protection to 2035
PatentsRoche

Roche’s Evrysdi Receives Patent Term Extension in China, Extending Protection to 2035

Show More